We performed a clinical study of pneumococcal endocarditis (PE) in adults at 15 major Spanish hospitals during a 21-year period . During this time, 63 patients had PE due to Streptococcus pneumoniae diagnosed. Of the 63 isolates recovered from these patients, 24 (38%) and 6 (10%) showed resistance to penicillin (minimum inhibitory concentration [MIC], 0.1-4 mg/mL) and cefotaxime (MIC, 1 mg/mL), respectively. Twenty-two (35%) of the patients died. Left-side heart failure, but not penicillin resistance, was independently associated with a higher risk of death (odds ratio, 1.33; 95% confidence interval, 1.04-1.71; P p ). Patients without meningitis who had PE due to penicillin-resistant S. pneumoniae could be treated with .026 high-dose penicillin or a third-generation cephalosporin if the MIC for penicillin was р1 mg/mL. For patients with concurrent meningitis, high doses of cefotaxime could be used if the MIC for cefotaxime was р1 mg/ mL. Early recognition of heart failure and surgery may help to decrease mortality.
cause of bacterial endocarditis [2, 3] , although the true incidence of this disease is unknown.
Pneumococcal resistance to penicillin has increased worldwide [4, 5] . However, the effect of pneumococcal resistance to penicillin reveals some differences between pneumococcal pneumonia and meningitis. More-severe underlying conditions have been associated with pneumococcal resistance to penicillin in patients with bacteremic pneumonia [6] but not in patients with meningitis [7] . Penicillin resistance has been associated with worse outcomes of bacteremic pneumococcal pneumonia [8] but not of pneumococcal meningitis [9] . Penicillin is not recommended for the treatment of penicillin-resistant meningitis, but it may be safely used for sepsis and pneumonia caused by pneumococci with intermediate resistance to penicillin (MIC, 0.1-1 mg/mL) [10] [11] [12] . Ceftriaxone and cefotaxime remain effective treatments for pneumococcal pneumonia if isolates have an MIC of !2 mg/mL [11] , but they may fail in the treatment of pneumococcal meningitis if isolates have an MIC of у1 mg/mL [12] .
Data are scarce regarding the treatment of pneumococcal endocarditis (PE) due to penicillin-resistant S. pneumoniae in adults [3, 13, 14] , and the optimal therapy for this entity remains unknown [10, 15, 16] . Therefore, we analyzed the effect of penicillin resistance of S. pneumoniae on the presentation, outcome, and treatment of PE in a prospective multicenter study of infective endocarditis in adults in Spain.
PATIENTS AND METHODS

Patients.
In 1978-1998, reports of infective endocarditis in adults were prospectively collected from 15 tertiary-care hospitals, by use of previously designed questionnaires, as part of a collaborative study. These 15 hospitals directly served an estimated population of 7 million adults during the study period, and data on pneumococcal bacteremia in adults were prospectively recorded at the microbiology laboratories of the participating hospitals. Twenty cases of PE included in this series have been partially described in Spanish-language medical journals [17] [18] [19] [20] [21] .
In our study, the following definitions were used:
1. An "adult" was defined as an individual у18 years of age.
2. A single episode of "pneumococcal bacteremia" was defined by the recovery of S. pneumoniae from у1 culture of blood samples obtained from 1 patient during the same period of hospitalization.
3. An anatomical site was considered the "source of the pneumococcal bacteremia" (1) if consistent focal manifestations preceded the diagnosis of bacteremia, and (2) if S. pneumoniae was recovered from specimens obtained from that site. CSF and synovial fluid were sites that were excluded from consideration as sources of bacteremia; isolation of S. pneumoniae from these 2 sites was considered to be a sign of septic metastasis.
4. Infective PE was diagnosed according to the standard criteria at the time of diagnosis [22] [23] [24] . However, for the purpose of this study, cases were categorized as "definite" or "possible" endocarditis by means of the Duke criteria [24] .
5. The risk factors for invasive pneumococcal disease and their specific criteria were as follows: alcoholism, if 180 g or 60 g of alcohol (for men and women, respectively) had been consumed daily [25] for at least the previous month; diabetes mellitus, if that disease had been diagnosed and if the patient was receiving hypoglycemic therapy; HIV infection, if the patient had ELISA and Western blot assay results that were positive for HIV type 1; injection drug use, if illicit substances repeatedly had been received intravenously for at least the previous month. Malignancy and cirrhosis required pathologic diagnosis.
6. Death was considered to be related to PE when it was caused by complications of PE that occurred during hospitalization. No systematic follow-up evaluation was performed after hospitalization ended.
Microbiological evaluation.
Microbiological evaluation was always performed at the laboratory of the hospital of admission. S. pneumoniae was identified by use of standard methods. Antibiotic susceptibility testing initially was performed using the disk-diffusion technique with Mueller-Hinton blood agar plates. A 1-mg oxacillin disk was used to detect strains that had decreased susceptibility to penicillin. Beginning in February 1982, S. pneumoniae organisms isolated from blood cultures underwent direct testing, by use of the agar dilution method, for determination of the MICs of at least the following antibiotics: penicillin, cefotaxime, erythromycin, and vancomycin. S. pneumoniae strains isolated before February 1982 were stored and later underwent testing for determination of antibiotic MICs by means of the agar dilution method, as described by Washington and Sutter [26] . Resistance to antimicrobial agents was defined according to the criteria of the National Committee for Clinical Laboratory Standards [27] . An S. pneumoniae strain was considered susceptible to penicillin if the MIC of penicillin was р0.06 mg/mL, intermediately susceptible if the MIC was 0.1-1.0 mg/mL, and resistant if the MIC was у2.0 mg/mL. An S. pneumoniae strain was considered susceptible to cefotaxime if the MIC of cefotaxime was р0.5 mg/mL, intermediately susceptible if the MIC was 1.0 mg/mL, and resistant if the MIC was у2.0 mg/mL. Antimicrobial therapy. Antimicrobial therapy was prescribed at the discretion of the medical team according to (1) the general recommendations for treatment of invasive pneumococcal infections at the time of diagnosis, and (2) the results of antibiotic susceptibility testing for each isolate.
Statistical analysis. Data were processed by use of the BMDP statistical software package (BMDP Statistical Software). Clinical manifestations of disease, echocardiographic findings, antimicrobial therapy, and mortality rates for individuals with PE due to penicillin-susceptible (MIC, !0.1 mg/mL) or penicillin-resistant (MIC, у0.1 mg/mL) strains of S. pneumoniae were compared by use of Student's t test, for continuous variables, and by Fisher's exact test, for categorical variables. The association between covariates and mortality was initially assessed by univariate analysis, and ORs then were determined by use of a logistic regression model. ORs and 95% CIs were calculated by use of EpiInfo, version 5.01 (Centers for Diseases Control and Prevention). An adjusted analysis was performed using models constructed by multiple logistic regression analysis [28] . Differences were considered significant only when by a bilateral test. P ! .05 
RESULTS
Incidence of PE.
During the 21-year study period (1978-1998), 63 patients were diagnosed with PE (1.4%) among the 4399 adults with infective endocarditis reported; these 63 cases of PE represented 1.2% of 5433 recorded episodes of pneumococcal bacteremia in adults. The median incidences of pneumococcal bacteremia and PE were 39.2 episodes and 0.36 cases, respectively, per 1 million adults per year. The annual incidence rates for pneumococcal bacteremia and for PE in adults tended to show slightly parallel increases during the study period (data not shown).
Clinical presentation and complications of PE. All cases of PE were community acquired. PE involved a native valve in 58 patients (92%) and a prosthetic valve in 5 patients (8%). Of the 7 patients who had previously experienced infective endocarditis due to bacteria other than S. pneumoniae, 5 were injection drug users with tricuspid endocarditis and 2 were individuals who had neoplasia and mitral or aortic endocarditis. Definite PE was diagnosed in 54 patients (86%). The remaining 9 patients (14%) had possible PE diagnosed either because echocardiography was not performed ( ) or because echon p 4 cardiography was performed but there was no evidence of endocardial involvement ( ), although the clinical picture n p 5 was consistent with endocarditis according to the Duke criteria [24] . There were no differences between definite and possible cases of PE with regard to the clinical characteristics or the proportion of penicillin-resistant isolates noted (data not shown).
Diagnosis of PE was not initially suspected in 16 patients (25%), and physicians were often misled by clinical manifestations that indicated the presence of other infectious diseases (e.g., sepsis, in 2 patients; pneumonia, in 6; meningitis, in 5; arthritis, in 1; and meningitis plus pneumonia, in 2) at the time of admission. For these 16 patients, diagnosis of endocarditis was made at a median of 8 days after admission (range, 1-61 days). Endocarditis was finally recognized through development of left-side heart failure ( ), persistence of fever n p 9 and development of embolic manifestations ( ), develn p 3 opment of meningitis ( ), detection of a new cardiac murn p 2 mur ( ), and unexpected diagnosis at necropsy ( ). n p 1 n p 1 Table 1 lists the clinical characteristics of the 63 patients with PE according to the susceptibility of S. pneumoniae isolates to penicillin. There were no significant differences between PE due to penicillin-susceptible S. pneumoniae and PE due to penicillin-resistant S. pneumoniae in terms of demographics, underlying conditions, underlying cardiopathy, clinical manifestations, source of bacteremia, valves affected, and echocardiographic characteristics. Table 2 lists the complications associated with PE according to the susceptibility of S. pneumoniae isolates to penicillin. There were no significant differences between PE due to penicillin-susceptible S. pneumoniae and PE due to penicillin-resistant S. pneumoniae with regard to the development of left-side heart failure, surgical valve replacement, CNS involvement, septic arthritis, pulmonary emboli, systemic emboli (excluding the CNS), renal insufficiency, or death.
Antimicrobial susceptibility of S. pneumoniae isolates that cause endocarditis.
S. pneumoniae was the only microorganism recovered from all but 1 patient, an injection drug user whose blood culture yielded Streptococcus pyogenes in addition to S. pneumoniae. There were 24 cases of PE due to penicillin-resistant strains (38%) and 39 cases of PE due to penicillin-susceptible strains (62%). Eighteen (75%) of the 24 penicillin-resistant isolates showed intermediate-level resistance. The MICs of the penicillin-resistant strains were as follows: 0.12 mg/mL ( ), 0.25 mg/mL ( ), 0.5 mg/mL n p 1 n p 2 ( ), 1 mg/mL ( ), 2 mg/mL ( ), and 4 mg/mL n p 4 n p 11 n p 4 (
). There were 6 cefotaxime-resistant strains that had a n p 2 cefotaxime MIC of 1 mg/mL; these 6 strains also exhibited high- Septic arthritis was noted in 9 patients. Emboli were noted in the eyes (retinal spots, conjunctival petechiae, and panophthalmitis; 5 patients) and in the peripheral arteries (5 patients), the heart (2 patients), and the kidney (2 patients). level resistance to penicillin (MIC, у2 mg/mL). Nineteen (30%) of 63 strains were resistant to erythromycin (MIC, 10.25 mg/ mL), and none exhibited resistance to vancomycin (MIC, 11 mg/mL). Figure 1 shows the distribution of S. pneumoniae isolates over time according to their susceptibility to penicillin.
Treatment of PE according to the antimicrobial susceptibility of isolates. Every patient received intravenously administered treatment with, at least, penicillin G sodium (2-5 million U q4h), a third-generation cephalosporin (either cefotaxime, 2-4 g q4h, or ceftriaxone, 2 g q24h), or vancomycin (1 g q12h). In general, higher doses of penicillin were used for individuals who had PE due to penicillin-resistant S. pneumoniae but who had no meningitis, whereas higher doses of cefotaxime were used for individuals who had PE due to penicillin-resistant S. pneumoniae and who also had meningitis. Some patients also received aminoglycosides (either gentamicin or amikacin; ), erythromycin ( ), or intrathecally n p 22 n p 1 administered vancomycin ( ). For patients who survived, n p 1 the median duration of antimicrobial therapy was 4.9 weeks (range, 4.1-6.4 weeks), regardless of the antibiotic regimen used, the susceptibility to penicillin, the side of the heart involved, and the presence or absence of meningitis. Table 3 summarizes the antibiotic therapy administered and the treatment outcome, on the basis of both the penicillin susceptibility of isolates and the presence or absence of meningitis. Some patients with PE due to penicillin-susceptible S. pneumoniae were treated with either ceftriaxone or vancomycin instead of with penicillin. Simplification of therapy was the only reason given for administration of 1 daily dose of cef- triaxone to 9 patients in the group with PE due to penicillinsusceptible S. pneumoniae. The group with PE penicillinsusceptible S. pneumoniae was given vancomycin because of allergy to b-lactam antibiotics ( ) or because of lack of n p 2 knowledge of the penicillin susceptibility status 1 seriously ill patient who died 2 days after admission to the hospital.
For 11 patients with a penicillin MIC of 1 mg/mL antimicrobial therapy included penicillin G sodium ( ), either n p 3 cefotaxime or ceftriaxone ( ), or vancomycin ( ). n p 6 n p 2 Three (27%) of these 11 patients had meningitis; all were treated with third-generation cephalosporins, and none died. For 6 patients with high-level resistance to penicillin (MIC, р2 mg/mL), antimicrobial therapy included either cefotaxime ( ) or vancomycin ( ). Two patients with high-level n p 4 n p 2 resistance to penicillin had meningitis, and both were treated with high dosages of cefotaxime (4 g q4h). One of the patients died, although the result of a CSF culture obtained on her third day of receiving antimicrobial therapy was negative.
Thirty-one patients underwent valve replacement with mechanical ( ) or biological ( ) prostheses. The indin p 22 n p 9 cations for surgery were left ventricular failure ( ), prosn p 27 thetic endocarditis without left ventricular failure ( ), n p 2 persistence of fever despite receipt of adequate antimicrobial therapy ( ), and CNS emboli ( ). The proportion of n p 1 n p 1 valves needing replacement was 58% (19 of 33) in cases of aortic PE, 43% (10 of 23) in mitral PE, and 0% (0 of 13) in tricuspid PE. The proportion of patients with PE due to penicillin-resistant S. pneumoniae for whom a cure was achieved with a medical-surgical approach (62%; 8 of 13 patients) was similar to that of patients with PE due to penicillin-susceptible S. pneumoniae who were cured (61%; 11 of 18 patients) (
) . P p .98
Outcome. Twenty-two patients (35%) died at a median of 13 days (range, 1-72 days) after PE was diagnosed. Before dying, 17 patients (77%) developed left-side heart failure and 9 (41%) developed CNS complications. Twelve of the 17 patients with left-side heart failure who died had undergone prosthetic valve replacement. The rates of surgery and mortality among the 51 patients with left-side involvement were 61% ( ) and 39% n p 31 ( ), respectively. In contrast, none of the 12 patients with n p 20 isolated right-side involvement needed surgery, and only 1 patient (8%), an injection drug user who rejected completion of antimicrobial therapy, died. Three (27%) of 11 patients with PE caused by pneumococci with a penicillin MIC of 1 mg/mL died, as did 1 (17%) of 6 such patients who had a penicillin MIC of 2 mg/mL.
The factors that influenced mortality in the univariate analysis are listed in table 4. All the variables in the univariate analysis were also introduced in the multivariate analysis. Because data were incomplete for 4 patients, 59 patients were considered for the multivariate analysis. For mortality, the only independent prognostic factor identified was the development of left-side heart failure (OR, 1.33; 95% CI, 1.04-1.71;
). P p .026
DISCUSSION
In this 21-year prospective study, we found a steady increase in penicillin resistance among S. pneumoniae strains that cause PE. However, we could not detect any influence of penicillin resistance on the clinical characteristics and complications of PE. Most of the penicillin-resistant isolates (75%) showed an intermediate level of resistance (MIC, 0.1-1 mg/mL). The MIC that indicated resistance to cefotaxime was 1 mg/mL for all patients (6 isolates; 10% of cases of PE), and it was noted only for penicillin-resistant strains, in accordance with findings of previous reports [10, 29] . No isolate was found to be resistant to vancomycin. These trends in antimicrobial resistance of strains that cause PE parallel those generally found for clinical isolates of S. pneumoniae throughout Spain [11, [30] [31] [32] . The mortality rate in our series was high (35%). Of interest, the mortality rate associated with PE, as determined by our study, is similar to that associated with other invasive pneumococcal infections, such as bacteremic pneumonia [11] and meningitis [33] [34] [35] , that have remained unchanged throughout the antibiotic era. Reduced susceptibility of pneumococcal isolates to penicillin was not associated with a higher mortality rate among patients with PE. For these patients, left-side heart failure was the only identified risk factor for mortality. Leftside heart failure has also been associated with increased mortality in association with infective endocarditis in general [36, 37] . In our study, 25% of the PE cases were not initially suspected at the time of admission. Our results emphasize the need to consider the possibility of endocarditis in every patient who presents with pneumococcal bacteremia. Early recognition of left-side heart failure and prompt cardiovascular surgery to replace the damaged valve may be essential to improve the prognosis of PE.
To our knowledge, this is the first study to provide therapeutical information for PE while taking account of both the susceptibility of S. pneumoniae to penicillin and the presence of meningitis. Penicillin G sodium (12-24 million U/day) or a third-generation cephalosporin (either ceftriaxone, 2 g/day, or cefotaxime, 2 g q4h) was effective therapy for PE due to penicillin-susceptible S. pneumoniae, irrespective of the presence or absence of meningitis. The presence of CNS involvement heavily influenced the choice of therapy for individuals with PE due to penicillin-resistant S. pneumoniae. Without CNS involvement, antimicrobial therapy similar to that used for patients with penicillin-susceptible strains was equally effective in treating patients with penicillin-resistant strains. Current levels of penicillin resistance may allow for the use of high-dose penicillin G sodium (24-30 million U/day) for individuals with PE due to penicillin-resistant strains but without CNS involvement, because these levels were caused by pneumococcal isolates with a penicillin MIC of !1 mg/mL. This approach has also been used successfully in patients with penicillin-resistant pneumococcal bacteremic pneumonia [11] and in an experimental model of PE due to penicillin-resistant organisms [38] . Recent recommendations indicate that all pneumococcal isolates that are not related to cases of meningitis and for which the MIC of penicillin is р1 mg/mL should be considered susceptible and that those with an MIC of 2 mg/mL or у4 mg/mL should be considered intermediately susceptible or resistant, respectively [39, 40] . Our data support such considerations because outcomes with penicillin therapy were not altered among patients infected by strains that had an MIC of р1 mg/ mL.
The emerging pneumococcal resistance to third-generation cephalosporins is a matter of increasing concern with regard to invasive infections, particularly meningitis. In our study, however, only 1 of 4 patients with cefotaxime-resistant PE (all of whom had a cefotaxime MIC of 1 mg/mL) and meningitis died, and the result of her CSF culture was already negative on the third day that she received high-dose cefotaxime therapy. These results agree with those of a small study in which 7 episodes of pneumococcal meningitis caused by isolates with decreased susceptibility to cefotaxime (MICs of 1 mg/mL for 5 episodes and 2 mg/mL for 2 episodes) were successfully treated with high doses of cefotaxime [41] . Nevertheless, our results should be considered with caution because of the low number of patients with meningitis who have cefotaxime-resistant isolates. Some authorities now recommend (1) empiric treatment of all cases of pneumococcal meningitis with either ceftriaxone or cefotaxime plus vancomycin or rifampin until susceptibility is known, and (2) maintenance of the latter regimen if isolates show cefotaxime MICs of у1 mg/mL [12, 42, 43] .
In summary, high-dose penicillin or a third-generation cephalosporin may be safely used for individuals without meningitis who have PE due to penicillin-resistant isolates with an MIC of р1 mg/mL. Individuals with meningitis who have PE due to penicillin-resistant strains for which the cefotaxime MIC is р1 mg/mL can be treated with high doses of cefotaxime, although the addition of vancomycin or rifampin probably should be considered if pneumococcal isolates show full resistance to cefotaxime (MIC, у2 mg/mL). Left-side heart failure, but not resistance to penicillin, is associated with a higher risk of death. Early recognition of heart failure and surgery may help to decrease the high mortality of PE. 
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